New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.

NCT07110662 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Toxic Epidermal Necrolysis
Immunotherapy
Cutaneous Adverse Drug Reactions (CADR)

Interventions

DRUG: DARATUMUMAB (DARZALEX®)

Sponsor

Hospices Civils de Lyon

Collaborators

[object Object]
[object Object]